Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Expert Opin Drug Discov. 2012 Jul 19;7(9):831–847. doi: 10.1517/17460441.2012.708335

Figure 7. Recently disclosed synthetic siderophore-antibiotic conjugates.

Figure 7

Compound 21, contains artemisinin functionality that is linked to mycobactin to afford for uptake by mycobacteria, as well as its proximal localization to a Fenton chemistry potentiator that activates the toxicity of the endoperoxide. Compounds 22 and 23 were recently described as leads by Pfizer, and are potent inhibitors of fluoroquin-resistant P. aeruginosa. BAL-30072 24 has successfully completed Phase I clinical trials and is cleared to start Phase II evaluations for effectiveness to treat multidrug resistant Gram negative infections.